CYP2D6 and Plasmodium vivax malaria: Variations in the genetic background of Cytochrome P450 2D6 (CYP2D6), for example, influence the metabolism of primaquine, an 8-aminoquinoline used to prevent relapses of vivax malaria, affecting how this drug is metabolised and impacting treatment outcomes in a given individual.33